The African Development Bank has signed a USD 15 million financing agreement with Biovac to expand vaccine manufacturing in South Africa. The project is expected to increase production capacity, support local vaccine supply chains and advance Africa's long-term pharmaceutical manufacturing capabilities.
The African Development Bank has finalized a financing agreement of up to USD 15 million with South African biopharmaceutical company Biovac to support the construction of a new multi-vaccine manufacturing facility in Cape Town. According to official disclosures, the investment will help expand domestic vaccine production and establish Africa's first end-to-end manufacturing capability for oral cholera vaccines while enabling local production of inactivated polio vaccines in South Africa.
The financing forms part of a broader expansion program that is expected to increase Biovac's annual manufacturing capacity to approximately 500 million vaccine doses. The facility will initially focus on oral cholera vaccines before adding production of vaccines targeting polio, pneumonia and meningitis. The project also incorporates technology-transfer partnerships with international vaccine developers to strengthen local manufacturing expertise and reduce reliance on imported vaccines.
The initiative carries broader significance for Africa's healthcare resilience, as the continent continues to depend heavily on imported vaccines despite facing a substantial burden of vaccine-preventable diseases. Expanding regional production capacity supports the African Union's objective of increasing local vaccine manufacturing while improving supply chain security, emergency preparedness and access to essential immunization programs. The investment is also expected to create approximately 340 full-time jobs and strengthen technical capabilities through workforce training and collaboration with academic institutions.
The project is likely to influence the pharmaceutical manufacturing, biotechnology and healthcare sectors across Africa by encouraging additional investment in regional life sciences infrastructure. Governments, healthcare providers, development finance institutions and vaccine suppliers could benefit from stronger local production capacity, reduced procurement risks and enhanced technology transfer. For investors and businesses, the agreement highlights continued momentum behind healthcare industrialization and pharmaceutical self-sufficiency as strategic priorities across emerging African markets.
The African Development Bank is a multilateral development finance institution that supports economic development and regional integration across Africa through public and private sector financing. Biovac is a South African vaccine manufacturer established through a public-private partnership to develop domestic vaccine production capabilities and supply routine immunization products across the region.
About GlobeNewsInfo
GlobeNewsInfo.com is a business news platform providing latest updates on global business developments, projects, and contract opportunities across diverse sectors and regions. The platform is designed to serve as a trusted source of information for companies, investors, and professionals worldwide.